IP Library Granted Patent US 8,946,269
Granted Patent B2
US 8,946,269 · App. 13/223,023 · Granted Feb 3, 2015

Crystalline forms of a factor Xa inhibitor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,269
App. No.
13/223,023
Granted
Feb 3, 2015
Kind
B2
Abstract

Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.

Claims (8)

1. A crystalline form of betrixaban maleate, which is Form II, having an X-ray powder diffraction pattern having at least the following characteristic peak locations of 10.1, 14.6, 18.0, and 22.0 degrees 2θ (each ±0.1 degrees 2θ).

2. The crystalline form of claim 1 , wherein the X-ray powder diffraction pattern has at least eight characteristic peak locations selected from 10.1, 14.6, 18.0, 19.6, 22.0, 23, 23.7, 24.5, 29.2, 29.5, 30.4, and 35.0 degrees 2θ (each ±0.1 degrees 2θ).

3. The crystalline form of claim 1 , having an X-ray powder diffraction pattern approximate to the X-ray powder diffraction pattern shown in FIG. 2 or 3 .

4. The crystalline form of claim 1 , having a melting point of about 213° C.

5. The crystalline form of claim 1 , having a unit cell containing two independent salt pairs of betrixaban and maleic acid wherein the imine N of betrixaban is protonated and forms an ionic H-bond to the maleic acid counter-ion.

6. The crystalline form of claim 1 , characterized by a unit cell structure with the following cell parameters at 100 K: a=8.284 A, b=18.082 A, c=18.681 A, α=71.22°, β=86.76°, γ=89.69°, and V=2645 A 3 .

7. The crystalline form of claim 1 , characterized by a unit cell structure with the following cell parameters at 273 K: a=8.419 A, b=18.113 A, c=18.73 A, α=71.14°, β=86.71°, γ=89.31°, and V=2699 A 3 .

8. A composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 1 .

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054975/0203 →
CHANGE OF NAME Recorded Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054976/0294 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
SECURITY INTEREST Recorded Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2012
From: CAPODANNO, VINCENT R.; MCNEVIN, MICHAEL; ZORAIDA ARROYO, ITZIA; BALL, RICHARD G.; MARGELEFSKY, ERIC L.; MAHER, TIMOTHY K.; CORCORAN, LIAM; WENSLOW, ROBERT M.
To: MERCK SHARP & DOHME
Reel/Frame 029466/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2012
From: PANDEY, ANJALI
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 029466/0783 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2012
From: MERCK SHARP & DOHME CORP.
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 028356/0211 →